ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 763

Comparison of Clinical Characteristics and Outcome between Isolated and Classic Lupus Nephritis

Kubra Bugdayli1, Cynthia S. Crowson2, Ladan Zand3, Mariam P. Alexander4, Lynn D. Cornell4 and Vaidehi R. Chowdhary5, 1Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Nephrology and Hypertension, Mayo Clinic, Rochester, MN, 4Anatomic Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN, 5Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Lupus, Lupus nephritis, outcomes, renal disease and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Comparison of clinical characteristics and outcome between isolated and classic lupus nephritis

Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE). Rarely, patients may present with LN alone and have no extra-renal clinical manifestations of lupus (isolated lupus nephritis, ILN). We aimed to describe the clinical characteristics of patients presenting with isolated LN and to study their treatment outcome and long term survival and its predictors compared to classic LN.

Methods: Subjects were identified by searching a pathologic renal biopsy database. Clinical records were reviewed for exclusion of infectious and secondary causes. Cases with isolated LN were defined per 2012 SLICC criteria; classic SLE patients had lupus nephritis along with extra-renal manifestations of lupus. Complete response (CR) was defined as proteinuria <0.5 g/24 h and serum creatinine (sCr) within 125% of the baseline value after the start of induction therapy. Partial response (PR) was defined as reduction of proteinuria of >50% (and at least <3.0 g/24 hours) plus sCr within 125% of the baseline value after the start of the induction therapy.

Results: 30 patients with isolated LN and 134 patients with classic LN were identified. The median age at the time of biopsy was 41 and 39 years, for the ILN and LN group, respectively. Majority were Caucasian; female to male ratio was 3:1 in ILN and 2:1 in the LN group. The median duration from renal symptoms to biopsy was 5.2 months for ILN and 1.2 for the LN group (p=0.013). Mean sCr was 1.7 mg/dl and 1.3 mg/dl and 24 hour proteinuria 8.5 and 4.9 g, respectively. A greater percentage of patients with ILN had hypertension at onset (83% versus 35% in LN, p<0.001) and interstitial fibrosis in biopsies (97% ILN versus 69% LN, p=0.018). The outcomes and survival among 18 ILN and 72 LN patients of class 3, 4 or mixed are noted in Table.

 

ILN

LN

Complete response (95% CI)

12 mo

5 year

10 year

23 (10, 54)

48 (29, 80)

62 (39, 99)

42 (32, 55)

67 (57, 80)

70 (59, 83)

Complete and/or partial (95% CI) response

12 mo

5 year

10 year

51 (32, 80)

69 (50, 95)

85 (64, 100)

58 (48, 71)

82 (73, 92)

88 (79, 98)

ESRD/Renal transplant (95% CI)

12 mo

5 year

10 year

6 (0, 40)

12 (3, 45)

30 (13, 71)

4 (1, 13)

17 (10, 30)

27 (17, 44)

Survival (95% CI)

12 mo

5 year

10 year

94 (84, 100)

88 (74, 100)

64 (40,100)

 

99 (96, 100)

94 (87, 100)

87 (77, 100)

Conclusion: The response rates and 10 year survival tended to be higher in the LN group compared to ILN. Possible late recognition and/or under treatment of this subset may be underlying the differences.


Disclosure: K. Bugdayli, None; C. S. Crowson, None; L. Zand, None; M. P. Alexander, None; L. D. Cornell, None; V. R. Chowdhary, None.

To cite this abstract in AMA style:

Bugdayli K, Crowson CS, Zand L, Alexander MP, Cornell LD, Chowdhary VR. Comparison of Clinical Characteristics and Outcome between Isolated and Classic Lupus Nephritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/comparison-of-clinical-characteristics-and-outcome-between-isolated-and-classic-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-clinical-characteristics-and-outcome-between-isolated-and-classic-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology